ULTRAGENYX PHARMACEUTICAL INC. Cash and Cash Equivalents, Period Increase (Decrease)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$60.63 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-21.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-21
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $40.08M, a 112.74% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$30.34M, a 134.79% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$68.75M.
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$1.62M.
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$60.63M, a 189.76% decline from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $67.55M, a 2.45% decline from fiscal 2015.
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $69.25M, a 309.81% increase from fiscal 2014.
- ULTRAGENYX PHARMACEUTICAL INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $16.90M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 47 month |
|---|---|---|---|---|---|
| 2017-12-31 | $40.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $9.74M derived: sum of 2 quarters · filed 2018-02-21 | -$59.01M derived: sum of 3 quarters · filed 2018-02-21 | -$60.63M 10-K · filed 2018-02-21 | |
| 2017-09-30 | -$30.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$99.09M derived: sum of 2 quarters · filed 2017-11-03 | -$100.71M 10-Q · filed 2017-11-03 | -$81.87M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2017-06-30 | -$68.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$70.37M 10-Q · filed 2017-07-28 | -$51.53M derived: sum of 3 quarters · filed 2018-02-21 | $35.68M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2017-03-31 | -$1.62M 10-Q · filed 2017-05-05 | $17.22M derived: sum of 2 quarters · filed 2018-02-21 | $104.43M derived: sum of 3 quarters · filed 2018-02-21 | $88.74M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-12-31 | $18.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $106.05M derived: sum of 2 quarters · filed 2018-02-21 | $90.36M derived: sum of 3 quarters · filed 2018-02-21 | $67.55M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $87.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $71.52M derived: sum of 2 quarters · filed 2017-11-03 | $48.71M 10-Q · filed 2017-11-03 | -$24.41M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-06-30 | -$15.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$38.50M 10-Q · filed 2017-07-28 | -$111.62M derived: sum of 3 quarters · filed 2018-02-21 | $2.72M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-03-31 | -$22.81M 10-Q · filed 2017-05-05 | -$95.92M derived: sum of 2 quarters · filed 2018-02-21 | $18.41M derived: sum of 3 quarters · filed 2018-02-21 | -$107.28M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2015-12-31 | -$73.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $41.22M derived: sum of 2 quarters · filed 2018-02-21 | -$84.47M derived: sum of 3 quarters · filed 2018-02-21 | $69.25M 10-K · filed 2018-02-21 | |
| 2015-09-30 | $114.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | -$11.35M derived: sum of 2 quarters · filed 2016-11-08 | $142.36M 10-Q · filed 2016-11-08 | $113.30M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | -$125.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $28.03M 10-Q · filed 2016-08-09 | -$1.04M derived: sum of 3 quarters · filed 2017-02-17 | $34.90M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $153.72M 10-Q · filed 2016-05-10 | $124.65M derived: sum of 2 quarters · filed 2017-02-17 | $160.59M derived: sum of 3 quarters · filed 2017-02-17 | $122.59M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | -$29.06M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $6.87M derived: sum of 2 quarters · filed 2017-02-17 | -$31.12M derived: sum of 3 quarters · filed 2017-02-17 | $16.90M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $35.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$2.06M derived: sum of 2 quarters · filed 2015-11-10 | $45.96M 10-Q · filed 2015-11-10 | $47.34M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | -$37.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $10.03M 10-Q · filed 2015-08-14 | $11.40M derived: sum of 3 quarters · filed 2016-02-26 | $3.94M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $48.02M 10-Q · filed 2015-05-12 | $49.40M derived: sum of 2 quarters · filed 2016-02-26 | $41.94M derived: sum of 3 quarters · filed 2016-02-26 | -$9.35M derived: sum of 4 quarters · filed 2016-02-26 | $55.45M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$6.08M derived: sum of 2 quarters · filed 2016-02-26 | -$57.37M derived: sum of 3 quarters · filed 2016-02-26 | -$78.76M 10-K · filed 2016-02-26 | |
| 2013-09-30 | -$7.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$58.75M derived: sum of 2 quarters · filed 2014-11-10 | -$80.14M 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | -$51.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$72.68M 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | -$21.39M 10-Q · filed 2014-05-12 | ||||
| 2012-12-31 | $75.55M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |